Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQB2450 or placebo + anlotinib + etoposide + carboplatin vs etoposide + carboplatin in extensive-stage small cell lung cancer
CTR20192538Phase 3Completed
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Dec 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of benmelstobart in small cell lung cancer (SCLC), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Started Dec 2019; status: completed.
02
Drugs
benmelstobart
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on CTR20192538.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20192538.